Moteur de recherche d’entreprises européennes
Financement britannique (634 526 £) : RaSTA (Approche de test de stérilité rapide) Ukri 01/08/2016 Recherche et innovation du Royaume-Uni, Royaume Uni
Vue d’ensemble
Texte
RaSTA (Approche de test de stérilité rapide)
| Abstract | Current safety methods for product release such as the compendial sterility test are inadequate for a large number of autologous cell and gene therapy products due to their short shelf life. This problem is exacerbated by the long complex manufacturing processes during which microbial contamination can occur. As a result sterility testing has to be performed during manufacture and the products released with an element of risk. This project, led by GSK and supported by the Cell Therapy Catapult and LGC, will address this issue by developing a rapid sterility test (<1hr) based on a novel technology to allow real time product release. The project will also develop a high sensitivity approaches which will quantify live and dead microbial contaminants for in-process testing and be used to validate the readout of the rapid sterility test. These technologies will be a major innovation for the field and will provide a much needed technical solution to allow cell and gene therapies to be tested for safety prior to their use. |
| Category | Collaborative R&D |
| Reference | 102608 |
| Status | Closed |
| Funded period start | 01/08/2016 |
| Funded period end | 31/01/2019 |
| Funded value | £634 526,00 |
| Source | https://gtr.ukri.org/projects?ref=102608 |
Participating Organisations
| GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED |
£215 173,00 |
| CELL THERAPY CATAPULT LIMITED |
£297 853,00 |
| LGC LIMITED |
£121 500,00 |
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Glaxosmithkline Research & Development Ltd., Londres, Royaume Uni.
